Wolfgang Miesbach: How ‘Benign’ PDE Inhibitors Shape Platelet Function
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn about a recent article by Meinrad Paul Gawaz et al, published in ScienceDirect:
”Do ‘benign’ PDE inhibitors quietly shape platelet function?
A recent study by Meinrad Paul Gawaz and co-authors from the University of Tübingen investigates how different phosphodiesterase (PDE) inhibitors modulate platelet signalling and thrombus formation via cAMP/cGMP pathways.
What the authors explored
They compared:
- A broad PDE blocker
- A PDE‑3–preferring inhibito
- A PDE‑5 inhibitor
…across platelet activation, aggregation assays and a collagen flow‑chamber models:
- ADP/P2Y12‑ and TRAP/PAR1‑driven platelet responses are more sensitive to PDE inhibition than collagen/GPVI signalling.
- Robust inhibition of activation and aggregation requires broad or combined PDE targeting, rather than blocking a single isoform.
- Under arterial shear, all tested inhibitors – including a PDE‑5 blocker – reduce thrombus formation, revealing effects not seen in routine PRP assays.
Why this matters
For patients on chronic PDE‑3/5 therapy (e.g. for vascular disease, pulmonary hypertension, erectile dysfunction), there may be a ‘hidden’ antithrombotic modulation that becomes clinically relevant when combined with aspirin, P2Y12 inhibitors or DOACs.”
Title: Effect of phosphodiesterase inhibitors on platelet function
Authors: Ravi Hochuli, Valerie Dicenta, Zoi Laspa, Manuel Sigle, Tobias Harm, Tatsiana Castor, Anne-Katrin Rohlfing, Meinrad Paul Gawaz
Read the Full Article on ScienceDirect.

Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation
-
Aug 21, 2026, 09:07Sujal Lohana: Building a Better Blood Donor–Seeker App
-
Aug 21, 2026, 08:55Robert Sidonio: Connecting Experts in Bleeding and Clotting Disorders